MedWatch

Bavarian Nordic: Covid-19 vaccine beats Pfizer's on several parameters

New studies will further explore tentative yet promising data on Bavarian Nordic and Adaptvac's Covid-19 vaccine candidates at a larger scale. According to Bavarian Nordic VP Investor Relations & Communications, the company still hopes to receive economic aid from Danish authorities.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Moods are bright at Bavarian Nordic after data from the first human trials of the company's Covid-19 vaccine candidate, ABNCoV2, confirm that Bavarian is holding a well-tolerated inoculation, showing higher antibody levels than approved vaccines from firms like Pfizer and partner Biontech, says Bavarian Nordic Vice President of Investor Relations & Communications Rolf Sass Sørensen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs